Fundraising Fox
Aizentx
San Diego, US · Founded 2023 · 16 employees on LinkedIn · 1 known investors
Find your way into Aizentx
Sign up to see every warm intro you have to Aizentx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aizentx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aizen is an AI-native biotechnology company that designs novel oral peptides using non-canonical amino acids and an AI platform called DaX to treat chronic immune disorders. The company develops both proprietary therapeutics and partners with biopharma companies to advance gut-restricted and systemic oral biologics.
Founders & leadership
Aizentx was founded in 2023 by David Van Valen and Ajay Kshatriya.
DV
David Van ValenFounderDavid Van Valen is an Assistant Professor in the Division of Biology and Bioengineering at Caltech with degrees in mathematics and physics from MIT, a Ph.D. in applied physics from Caltech, an M.D. from UCLA, and postdoctoral training in bioengineering at Stanford; his research spans imaging, genomics, and machine learning for single-cell analysis.
AK
Ajay KshatriyaFounderAjay Kshatriya is CEO of Aizen Therapeutics, an AI-native biotech company developing oral peptides for chronic immune disorders. He previously founded Biota, an environmental genomics company acquired by Novozymes, and worked in venture capital at XSeed Capital and product operations at Genentech; he holds engineering degrees from UC Berkeley and Stanford and an MBA from Berkeley-Haas.
BG
Bernhard GeierstangerPhDBernhard Geierstanger is a PhD with biotechnology industry experience in drug discovery and platform technology development. He is a co-founder of Aizentx, an AI-native biotech company developing oral peptides using non-canonical amino acids to treat chronic immune disorders.
TP
Todd PetersonFounderTodd Peterson holds a PhD and brings over 30 years of experience in biotechnology and life sciences R&D, including work in molecular and cell biology, genomics, and product development across clinical diagnostics and drug discovery. He founded GenApex Biotechnology Consulting, a life science advisory practice providing board services and investment guidance.
Investors · 1
Related companies · 3
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
ClementiaIpsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Companies working in the same space as Aizentx.
Frequently asked questions
- What does Aizentx do?
- Aizen is an AI-native biotechnology company that designs novel oral peptides using non-canonical amino acids and an AI platform called DaX to treat chronic immune disorders. The company develops both proprietary therapeutics and partners with biopharma companies to advance gut-restricted and systemic oral biologics.
- Who founded Aizentx?
- Aizentx was founded by David Van Valen, Ajay Kshatriya in 2023.
- Who are Aizentx's investors?
- Aizentx's investors include Madrona Venture Group.
- Where is Aizentx headquartered?
- Aizentx is headquartered in San Diego, US.